These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29687032)

  • 1. Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in
    Morita D; Nishio N; Saito S; Tanaka M; Kawashima N; Okuno Y; Suzuki S; Matsuda K; Maeda Y; Wilson MH; Dotti G; Rooney CM; Takahashi Y; Nakazawa Y
    Mol Ther Methods Clin Dev; 2018 Mar; 8():131-140. PubMed ID: 29687032
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Saito S; Nakazawa Y; Sueki A; Matsuda K; Tanaka M; Yanagisawa R; Maeda Y; Sato Y; Okabe S; Inukai T; Sugita K; Wilson MH; Rooney CM; Koike K
    Cytotherapy; 2014 Sep; 16(9):1257-69. PubMed ID: 25108652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Good manufacturing practice-grade generation of CD19 and CD123-specific CAR-T cells using piggyBac transposon and allogeneic feeder cells in patients diagnosed with B-cell non-Hodgkin lymphoma and acute myeloid leukemia.
    Mucha M; Štach M; Kaštánková I; Rychlá J; Vydra J; Lesný P; Otáhal P
    Front Immunol; 2024; 15():1415328. PubMed ID: 39192973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel xeno-free and serum-free culturing condition to improve piggyBac transposon-based CD19 chimeric antigen receptor T-cell production and characteristics.
    Sanyanusin M; Tudsamran S; Thaiwong R; Tawinwung S; Nishio N; Takahashi Y; Hirankarn N; Suppipat K
    Cytotherapy; 2023 Apr; 25(4):397-406. PubMed ID: 36517366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.
    Bishop DC; Xu N; Tse B; O'Brien TA; Gottlieb DJ; Dolnikov A; Micklethwaite KP
    Mol Ther; 2018 Aug; 26(8):1883-1895. PubMed ID: 29861327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
    Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
    Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzymatically produced piggyBac transposon vectors for efficient non-viral manufacturing of CD19-specific CAR T cells.
    Kaštánková I; Štach M; Žižková H; Ptáčková P; Šmilauerová K; Mucha M; Šroller V; Otáhal P
    Mol Ther Methods Clin Dev; 2021 Dec; 23():119-127. PubMed ID: 34631931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR T Cell Generation by
    Bishop DC; Caproni L; Gowrishankar K; Legiewicz M; Karbowniczek K; Tite J; Gottlieb DJ; Micklethwaite KP
    Mol Ther Methods Clin Dev; 2020 Jun; 17():359-368. PubMed ID: 32071928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients.
    Zhang Y; Zhang Z; Ding Y; Fang Y; Wang P; Chu W; Jin Z; Yang X; Wang J; Lou J; Qian Q
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3725-3734. PubMed ID: 34032893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies.
    Tsukahara T; Iwase N; Kawakami K; Iwasaki M; Yamamoto C; Ohmine K; Uchibori R; Teruya T; Ido H; Saga Y; Urabe M; Mizukami H; Kume A; Nakamura M; Brentjens R; Ozawa K
    Gene Ther; 2015 Feb; 22(2):209-15. PubMed ID: 25427612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia.
    Magnani CF; Mezzanotte C; Cappuzzello C; Bardini M; Tettamanti S; Fazio G; Cooper LJN; Dastoli G; Cazzaniga G; Biondi A; Biagi E
    Hum Gene Ther; 2018 May; 29(5):602-613. PubMed ID: 29641322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous antigen-presenting cells efficiently expand
    Nakamura K; Yagyu S; Hirota S; Tomida A; Kondo M; Shigeura T; Hasegawa A; Tanaka M; Nakazawa Y
    Mol Ther Methods Clin Dev; 2021 Jun; 21():315-324. PubMed ID: 33898630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells.
    Štach M; Ptáčková P; Mucha M; Musil J; Klener P; Otáhal P
    Cytotherapy; 2020 Dec; 22(12):744-754. PubMed ID: 32950390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
    Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
    Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gene-modified T-cell therapy using chimeric antigen receptors for pediatric hematologic malignancies].
    Nakazawa Y
    Rinsho Ketsueki; 2016 Jun; 57(6):701-8. PubMed ID: 27384848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct Delivery of
    Tanaka K; Kato I; Tanaka M; Morita D; Matsuda K; Takahashi Y; Nakahata T; Umeda K; Hiramatsu H; Adachi S; Takita J; Nakazawa Y
    Mol Ther Oncolytics; 2020 Sep; 18():37-46. PubMed ID: 32637579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
    Li HH; Zhu P; Wu XQ; Liu YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.